In study of 30,000 mild-to-moderate COVID-19 patients, antibody responses can persist for five months

October 28, 2020

Researchers who studied antibody responses in 30,000 patients with mild-to-moderate COVID-19 report that the patients' antibodies were relatively stable for at least five months. Although the results do not yet provide conclusive evidence that these levels protect from reinfection, Ania Wajnberg and colleagues say they "believe it is very likely that they will decrease the odds ratio of reinfection and may attenuate disease in the case of breakthrough infection." As the number of daily COVID-19 cases worldwide continues to mount, the nature of the humoral immune response, which includes an antibody response, remains uncertain. Assessing the antibody response in mild and asymptomatic cases is of particular importance since these cases constitute the majority of infections. In March 2020, the Mount Sinai Health System in New York City began to screen individuals for antibodies to SARS-CoV-2 to recruit volunteers as donors for convalescent plasma therapy. By 6 October, Mount Sinai had screened 72,401 individuals, with a total of 30,082 individuals testing positive, many of whom showed notable IgG antibody responses. Wajnberg and colleagues studied this cohort to dissect the longevity and potency of their anti-SARS-CoV-2 antibody responses. Using a well-established assay, they evaluated neutralizing effects of the antibodies, critical to understanding possible protective effects. They report that spike binding as measured by the assay is roughly correlated with virus neutralization. To evaluate longevity of the antibody response, the authors recalled 121 plasma donors. In these patients, they found stable antibody titers for a period approximating five months. The authors note their findings contradict other work suggesting antibody responses do not have much longevity, including work published in June 2020 that showed waning titers eight weeks after virus infection. However, among other differences, the antibodies measured in that report targeted a different viral antigen. This may suggest the stability of the antibody response over time depends on the target antigen, the authors say. They plan to follow their cohort over longer intervals to help inform if and how enduring antibody responses protect from reinfection. "We believe it is imperative to swiftly perform studies to investigate and establish a correlate of protection from infection with SARS-CoV-2." This could inform policy regarding the COVID-19 pandemic, they say, and would be beneficial to vaccine development efforts.
-end-


American Association for the Advancement of Science

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.